Glutamate a big target for drug developers

The New York Times' Alex Berenson looks at the wave of new research programs focused on the neurotransmitter glutamate as a therapy for schizophrenia. Eli Lilly's Darryle D. Schoepp recognized its potential in the fall of 2006, and other drug discoverers weren't far behind as a number of developers jumped into the field. All approved therapies for schizophrenia target dopamine, and the glutamate connection opened up a host of possibilities for depression, Alzheimer's and other indications as well.

"I don't think people appreciate how much money, time and good technical research goes into what we do," Schoepp told the Times. "Sometimes, people think the idea is the thing. I think the idea can be the easy part."

- read the article from The New York Times

Related Articles:
Potential new drug found for schizophrenia. Report
Addex is talking deals as interest in a new class of drugs. Profile

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.